Anti-Human CD151 – Purified in vivo GOLD™ Functional Grade

Clone 50-6 is a monoclonal antibody that targets CD151, and in in vivo mouse studies, it is primarily used to inhibit metastasis of human tumor cells by binding to the CD151 antigen, which is associated with cell migration and metastasis.

In these studies:

• Clone 50-6 (Mouse IgG1) is administered to mice, often intravenously or intraperitoneally, to specifically bind CD151 on human cancer cells that have been introduced into the mouse.
• The antibody's ability to inhibit metastasis is measured by the reduction in tumor spread within the animal, with treated groups compared to those given isotype controls.
• The antibody may be used in assays such as immunostaining, flow cytometry, or tumor growth and metastasis inhibition experiments, and isotype-matched controls (Mouse IgG1) are essential for validating specificity and excluding non-specific effects.
• The referenced studies indicate that mAb 50-6 was generated by subtractive immunization and recognizes a 29 kDa cell surface antigen, later identified as CD151/PETA-3/TM4SF, in both human tumor and transfected cells. In vivo, administration of mAb 50-6 results in significant inhibition of metastasis.

Summary of typical use in mouse studies:

• Targeted antibody treatment: Clone 50-6 is given to mice bearing human tumor xenografts.
• Assessment: Researchers track the extent of metastasis in experimental and control animals using histological or imaging approaches.
• Controls: Matching Mouse IgG1 isotype controls are used for proper experimental comparison.

This antibody is an example of an in vivo functional grade primary antibody validated for use in mouse models, specifically targeting CD151 to study its role in tumor progression and metastasis.

Commonly used antibodies or proteins used with 50-6 (an anti-CD151 monoclonal antibody) in the literature typically depend on the context of the experiment, but there are several that are regularly paired in immunophenotyping or cancer/epithelial biology studies.

• Other Tetraspanins: CD151 is part of the tetraspanin family and is often studied alongside other tetraspanins such as CD9, CD63, and CD81 to analyze cell surface complex formation and tetraspanin-enriched microdomains.

• Integrins: Since CD151 interacts with integrins (notably ?3?1, ?6?1, and ?6?4), antibodies targeting these integrins are frequently used in co-immunoprecipitation (co-IP), flow cytometry, or immunofluorescence studies to elucidate adhesion or signaling complexes.

• Epithelial and Tumor Markers: In cancer or cell biology research, pan-cytokeratin, EpCAM, CD44, and E-cadherin antibodies are commonly used together with 50-6 CD151 to study epithelial cell phenotype and cancer cell populations.

• Leukocyte Markers: In flow cytometry panels, CD151 antibodies like 50-6 may be used alongside leukocyte markers such as CD45, CD3, CD4, or CD8 for detailed immunophenotyping, especially when understanding CD151’s role in immune cell function.

• Functional Markers: For studies related to cell activation, proliferation, or signaling, antibodies against markers like phospho-AKT, mTOR, or S6K (since these pathways are downstream of many integrin/tetraspanin interactions) may also be included in antibody panels.

Flow cytometry and immunofluorescence panels that include 50-6 will almost always include multiple lineage or functional antibodies to allow multiparameter analysis, consistent with best practices in antibody-based research.

If you are seeking specific combinations reported in primary literature, referencing articles or protocols where the 50-6 clone is cited often reveals that it appears together with markers relevant to the cell type or biological process of interest—most frequently integrins, other tetraspanins, and cell lineage markers.

If you want a precise list from a particular context (e.g., a particular tissue or disease), more specific details can be provided.

Overview

The term "clone 50-6" is not directly referenced in the provided search results, and there is no scientific analysis or paper in the first several pages referencing a specific "clone 50-6" by that identifier. However, results regarding clone pSC101 are discussed in the context of seminal work in DNA cloning—specifically, as recounted by Stanley N. Cohen in his personal account.

If your query refers to a specific "clone 50-6" from a particular organism, system, or technology (e.g., gene, cell line, or code clone), the provided search does not contain that information. Below, I summarize the most relevant scientific findings related to DNA cloning (Cohen, 1973), which many associate with key early clones like pSC101—a foundational cloning vector—and explain the significance of those findings.

Key Scientific Findings in Early DNA Cloning

• Creation of pSC101: The plasmid pSC101 was created accidentally during early DNA cloning experiments, where mechanical shearing and selection identified a small plasmid (pSC101) expressing only tetracycline resistance. This plasmid became a cornerstone for DNA cloning technology.
• Discovery of Vector Properties: pSC101 had both a selectable marker (antibiotic resistance) and autonomous replication capabilities, making it an effective vector for DNA cloning. This demonstrated that for robust DNA cloning, a single vector fragment must include both a selectable gene and replication functions.
• Gene Cloning via Restriction Enzymes: The use of restriction enzyme EcoRI was pivotal. Scientists could cut DNA at specific sites, allowing for reproducible, targeted insertion of foreign DNA fragments. This led to the successful cloning of the kanamycin resistance gene from plasmid R6-5 using pSC101 as a vector.
• Early Demonstration of Gene Propagation: These experiments showed that foreign DNA (including genes from unrelated species) could be propagated in bacteria, laying the groundwork for recombinant DNA technology, gene therapy, and molecular biology research.
• Scientific Collaboration: The progress in cloning technology was heavily dependent on collaboration between groups (Cohen, Boyer, Morrow), especially for identifying and selecting clones carrying foreign DNA without direct phenotypic markers.

Limitations of the Search

If "clone 50-6" refers to a specific entity not related to the Cohen–Boyer DNA cloning experiments (e.g., a cell line, a particular clone in a laboratory organism such as yeast or zebrafish, or a code clone in computer science), the cited literature does not contain information about it. The only clone-related scientific findings described in the search are those related to pSC101 and the origins of DNA cloning technology.

Conclusion

If "clone 50-6" is a unique identifier from your research context, you must specify the organism, system, or field (e.g., molecular biology, immunology, cell biology, or software engineering) for targeted information.

If you are referring to the foundational DNA cloning work, the key findings are the establishment of pSC101 as a cloning vector, the demonstration of gene cloning using restriction enzymes, and the feasibility of propagating foreign DNA in bacterial cells—milestones that revolutionized molecular biology.

There is no published evidence in the provided results detailing the dosing regimens of clone 50-6 across mouse models. None of the cited literature or antibody guides specifically mention clone 50-6, its target, or its pharmacological context in vivo. Thus, an evidence-based answer about dose, frequency, or variation between models for clone 50-6 is not possible from the available search data.

If clone 50-6 refers to a commonly used research antibody, its dosing regimen would typically be informed by:

• Target antigen abundance
• Intended experimental effect (e.g., cell depletion, functional blocking, immune modulation)
• Mouse strain sensitivity

For comparable monoclonal antibodies in mouse models:

• Intraperitoneal or intravenous dosing is standard, with amounts ranging from 50–300 ?g per mouse, administered once or several times per week depending on the pharmacokinetics and desired immunological effect.

Since no information about clone 50-6 was present in the search results, any recommendation beyond the above generalization would be speculative. For precise guidance, refer to the product datasheet from the antibody supplier or relevant peer-reviewed studies using clone 50-6.

If you provide the target or context for clone 50-6 (such as antigen, company, or disease model), a more precise or inferential dosing recommendation may be possible.